PAS
MRNA icon

Partnervest Advisory Services’s Moderna MRNA Stock Holding History

Partnervest Advisory Services’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$245K Buy
+3,461
New +$241K 0.08% 202

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Partnervest Advisory Services's MRNA Position: Q3 2020 in Review

Partnervest Advisory Services opened a new position in Moderna (MRNA) in Q3 2020: 3,461 shares worth $245K. The stake represents 0.08% of the portfolio and ranks #202 among its holdings.

547 funds tracked by Wall St. Rank hold MRNA as of Q3 2020.

  • Partnervest Advisory Services held 3,461 shares of Moderna worth $245K as of Q3 2020.
  • Moderna was a new Partnervest Advisory Services position in Q3 2020.
  • Moderna made up 0.08% of Partnervest Advisory Services's portfolio in Q3 2020, its #202 holding.
  • 547 funds tracked by Wall St. Rank held Moderna as of Q3 2020.

Based on Partnervest Advisory Services's 13F filing for Q3 2020, filed 3 Nov 2020.